Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $6.3700 (4.6%) ($6.3700 - $6.3700) on Tue. Feb. 9, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.57% (three month average) | RSI | 72 | Latest Price | $6.3700(4.6%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 2.1% a day on average for past five trading days. | Weekly Trend | ADMS advances 9.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) SIL(25%) SLV(21%) URA(13%) MCHI(12%) TLT(12%) | Factors Impacting ADMS price | ADMS will decline at least -2.285% in a week (0% probabilities). JETS(-20%) CEMB(-19%) REMX(-14%) VCSH(-12%) XLE(-10%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.285% (StdDev 4.57%) | Hourly BBV | 1.4 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $5.98(6.52%) | 10 Day Moving Average | $5.93(7.42%) | 20 Day Moving Average | $5.35(19.07%) | To recent high | -4.4% | To recent low | 27.4% | Market Cap | $180m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |